Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16629693 | 0.91 | GRM4 (0.35) | ALOX5KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL20435115 | 0.87 | ALOX5 (0.43) | ALOX5KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL17081199 | 0.87 | ALOX5 (0.43) | ALOX5KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL16629737 | 0.87 | GRM4 (0.36) | KDM4EMAPTHPGDHSD17B10ALDH1A1 | |
| SCHEMBL16629928 | 0.85 | ALOX5 (0.38) | ALOX5KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL24958102 | 0.85 | KDM4E (0.38) | KDM4EMAPTHPGDHSD17B10ALDH1A1 | |
| SCHEMBL20435221 | 0.85 | ALOX5 (0.44) | ALOX5KDM4EL3MBTL1GGPS1KMT2A | |
| SCHEMBL16629734 | 0.84 | PIM1 (0.37) | ALOX5KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL24889155 | 0.84 | ALOX5 (0.44) | ALOX5L3MBTL1GGPS1TDP1CYP19A1 | |
| SCHEMBL20435130 | 0.84 | ALOX5 (0.46) | ALOX5KDM4EMAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407394-B2 | Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices | MERCK PATENT GMBH (DE) | 2019-09-10 | — | — | US | disclosed |
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| WO-2015049022-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | KCNQ1, KCNH1, KCNQ2 | ALOX5 3677/4885KDM4E 1939/4885MAPT 2400/4885 |
| US-10407394-B2 | Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices | KCNQ1, KCNH1, KCNQ2 | ALOX5 3677/4885KDM4E 1939/4885MAPT 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.